Tag Archives: Amyotrophic lateral sclerosis

Scientists measure communication between stem cell-derived motor neurons, muscle cells

In an effort to identify the underlying causes of neurological disorders that impair motor functions such as walking and breathing, UCLA researchers have developed a novel system to measure communication between stem cell–derived motor neurons and muscle cells in a Petri dish.

The study provides an important proof of principle that functional motor circuits can be created outside the body using these neurons and cells and that the level of communication, or synaptic activity, between them can be accurately measured by stimulating the motor neurons with an electrode and then tracking the transfer of electrical activity into the muscle cells
Read More…

Stem Cells startup to fight ALS

USC Stem Cell researcher Justin Ichida has marshaled the expertise of pharmaceutical company Sanofi and startup DRVision Technologies, along with $1.5 million in federal funding, to find new drugs in the fight against amyotrophic lateral sclerosis, or Lou Gehrig’s disease.

ALS patients suffer from the death of the cells that transmit signals from the brain to the muscles, called motor neurons, leading to progressive paralysis and usually resulting in fatal respiratory failure within three to five years of diagnosis.

The three-year grant comes from the Department of Defense. Each year, the DoD funds two ALS Therapeutic Development Awards because military veterans
Read More…

Neuralstem gets FDA OK for Stem cell trial for ALS treatment

Neuralstem Inc. has received the green light to begin the first human stem cell trial to treat Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig’s disease. The company’s stock soared on the news.

Neuralstem has only received approval for the first stage of the trial that would consist of 12 patients who will receive stem cell injections in the lumbar area of the spinal cord.

Neuralstem said the trial will be under the direction of principal investigator Dr. Eva L. Feldman, Director of the University of Michigan Health System ALS Clinic and the Program for Neurology Research & Discovery.
Read More…

Emory Conducting Landmark Study to Treat ALS

Emory University researchers are participating in a groundbreaking clinical trial to treat patients with amyotrophic lateral sclerosis (ALS) using human neural stem cells.

The Phase 1 trial, will assess the safety of stem cells, and the surgical procedures and devices required, for multiple injections of the cells directly into the spinal cord.

“This is the first U.S. clinical trial of stem cell injections into the spinal cord for the treatment of ALS,” says principal researcher Jonathan Glass, professor of neurology in the School of Medicin, and director of the Emory ALS Center. “Our main goal in this early phase is to
Read More…

FDA Approves Continuation of ALS Stem Cell Trial

Emory University researchers have received approval from the Food and Drug Administration (FDA) to advance to the next phase of a landmark trial to treat patients with Amyotrophic Lateral Sclerosis (ALS) using human neural stem cells.

The Phase I trial, currently underway exclusively at Emory University, is designed to assess the safety of implanting neural stem cells into the spinal cord in up to 18 people with ALS and began in January 2010. The first 12 patients received neural stem cell transplants in the lumbar, or lower, region of the spinal cord. After reviewing safety data from these patients, the
Read More…